Palatin Technologies Inc. (PTN)

[BesaoT35]

Vyleesi aka PTN-141 aka bremelanotide is in fact an effective aphrodisiac. Somehow this fact just got buried. This is counterintuitive. The drug works, but the company failed to market the drug effectively.

The DED treatment uses a novel mechanism of action. It could be more effective than the SOC. Phase 3 with finish fairly soon.

Informing the shareholder is not a high priority with the PTN management. Vyleesi could get discovered by women and shared with husbands and other partners. Men benefit even more than do women on average. This never gets discussed. Why should men be denied?